Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BRCA1 Mutation Clear all
Not listed No phase listed Observational

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

NCT00897455
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
DNA analysis, mutation analysis, polymorphism analysis, laboratory biomarker analysis, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 80 Years · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 21, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT06177171
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions
Olaparib, ASTX727
Drug
Lead sponsor
Varun Monga, MBBS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Enrolling by invitation Not applicable Interventional

Genetic Education in BRCA Families

NCT03544983
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Web + Streamlined Telephone Genetic Information
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

NCT02393794
View directory record Official record
Conditions
Triple-Negative Breast Cancer, Breast Cancer
Interventions
Romidepsin, Cisplatin, Nivolumab
Drug
Lead sponsor
Priyanka Sharma
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
7
States / cities
Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

NCT02957981
View directory record Official record
Conditions
Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Web-based Counseling, Standard Care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 70 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 21, 2026, 6:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

NCT00590109
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood test, Questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 21, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

NCT06972719
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Experimental Arm, SOC Arm
Behavioral
Lead sponsor
Duke University
Other
Eligibility
19 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Terminated Phase 1 Interventional

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT05252390
View directory record Official record
Conditions
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
Interventions
NUV-868, Olaparib, Enzalutamide
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Recruiting Not applicable Interventional

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NCT04251052
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

NCT01104259
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
veliparib, cisplatin, vinorelbine tartrate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

NCT06534424
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Recruiting No phase listed Observational

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

NCT02478892
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen, Blood sample collection for research
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311
View directory record Official record
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions
AZD 1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 21, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04367675
View directory record Official record
Conditions
BRCA1/2 Mutation
Interventions
INO-5401, INO-9012, Cellectra 2000
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Recruiting Phase 1 Interventional

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

NCT07356453
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
FORX-428
Drug
Lead sponsor
FoRx Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 21, 2026, 6:16 AM EDT
Withdrawn Phase 2 Interventional

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

NCT01661868
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 21, 2026, 6:16 AM EDT
Not listed Phase 1 Interventional

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

NCT02950064
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Support for BRCA Testing in Ethnically Diverse Women

NCT03470402
View directory record Official record
Conditions
Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Interventions
RealRisks, BNAV, iNYP, Standard Educational Material, High-Risk Message
Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 21, 2026, 6:16 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

NCT04718675
View directory record Official record
Conditions
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
Interventions
KB-0742
Drug
Lead sponsor
Kronos Bio
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Fountain Valley, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 21, 2026, 6:16 AM EDT
Withdrawn No phase listed Observational

Clinical Outcomes in Hereditary Cancer

NCT00580021
View directory record Official record
Conditions
Breast Cancer, Pancreatic Cancer
Interventions
Genotyping
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 21, 2026, 6:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)

NCT04866992
View directory record Official record
Conditions
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Ductal Carcinoma in Situ, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, BRCA1 Mutation, BRCA2 Mutation
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 21, 2026, 6:16 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

FaCT Trial (Facilitated Cascade Testing Trial)

NCT04613440
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing, Telephone Counseling
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 21, 2026, 6:16 AM EDT